Moderna will discontinue the development of mRNA-1647 in CMV after the trial failure. Image credit: Tada Images / Shutterstock.com. Moderna is terminating the development of an mRNA vaccine in ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. A vaccine Moderna has long been developing for the ...
Moderna plans to continue evaluating mRNA-1647 in an ongoing Phase 2 trial for bone marrow transplant patients, where the vaccine could potentially suppress disease associated with CMV reactivation.
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...
CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company’s ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min While Moderna downplayed the ...
Oct 22 (Reuters) - Moderna (MRNA.O), opens new tab said on Wednesday it would stop developing its experimental vaccine to prevent cytomegalovirus, a virus that can cause birth defects, after it failed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback